Literature DB >> 15040862

Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer.

Sean R Downing1, Kristen T Hennessy, Miyako Abe, Judith Manola, Daniel J George, Philip W Kantoff.   

Abstract

Several genetic loci are suspected to be involved in hereditary prostate cancer, including the hereditary prostate cancer 1 (HPC1) locus at chromosome 1q24-25. The ribonuclease L (RNase L) gene has been reported as the putative hereditary prostate cancer gene located at HPC1. If this is the case, mutations of RNase L should be found at a greater frequency in familial cancers than in sporadic prostate cancers. Examination of familial and sporadic cases of prostate cancer by polymerase chain reaction and DNA sequencing resulted in a mutational frequency rate that was not statistically different between the 2 forms of the disease. These results suggest that the mutations examined within this study are rare and may contribute to very few familial prostate cancers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15040862     DOI: 10.3816/cgc.2003.n.027

Source DB:  PubMed          Journal:  Clin Prostate Cancer        ISSN: 1540-0352


  10 in total

Review 1.  A scientific journey through the 2-5A/RNase L system.

Authors:  Robert H Silverman
Journal:  Cytokine Growth Factor Rev       Date:  2007-07-27       Impact factor: 7.638

Review 2.  Diverse functions of RNase L and implications in pathology.

Authors:  Catherine Bisbal; Robert H Silverman
Journal:  Biochimie       Date:  2007-02-20       Impact factor: 4.079

Review 3.  The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome.

Authors:  Robert H Silverman; Carvell Nguyen; Christopher J Weight; Eric A Klein
Journal:  Nat Rev Urol       Date:  2010-06-01       Impact factor: 14.432

4.  Evaluation of cellular determinants required for in vitro xenotropic murine leukemia virus-related virus entry into human prostate cancer and noncancerous cells.

Authors:  Sushma Bhosle; Suganthi Suppiah; Ross Molinaro; Yuying Liang; Rebecca Arnold; William Diehl; Natalia Makarova; Jerry Blackwell; John Petros; Dennis Liotta; Eric Hunter; Hinh Ly
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

5.  Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease.

Authors:  Alice Rusmevichientong; Samson A Chow
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

6.  XMRV Discovery and Prostate Cancer-Related Research.

Authors:  David E Kang; Michael C Lee; Jaydip Das Gupta; Eric A Klein; Robert H Silverman
Journal:  Adv Virol       Date:  2011-06-21

7.  Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant.

Authors:  Anatoly Urisman; Ross J Molinaro; Nicole Fischer; Sarah J Plummer; Graham Casey; Eric A Klein; Krishnamurthy Malathi; Cristina Magi-Galluzzi; Raymond R Tubbs; Don Ganem; Robert H Silverman; Joseph L DeRisi
Journal:  PLoS Pathog       Date:  2006-03-31       Impact factor: 6.823

8.  Selection and cloning of poly(rC)-binding protein 2 and Raf kinase inhibitor protein RNA activators of 2',5'-oligoadenylate synthetase from prostate cancer cells.

Authors:  Ross J Molinaro; Babal Kant Jha; Krishnamurthy Malathi; Sooryanarayana Varambally; Arul M Chinnaiyan; Robert H Silverman
Journal:  Nucleic Acids Res       Date:  2006-12-01       Impact factor: 16.971

Review 9.  Molecular pathways in prostate cancer.

Authors:  Evangelos Mazaris; Alexios Tsiotras
Journal:  Nephrourol Mon       Date:  2013-06-08

10.  Xenotropic Murine Leukemia Virus-Related Virus and RNase L R462Q Variants in Iranian Patients With Sporadic Prostate Cancer.

Authors:  Farhad Babaei; Ali Ahmadi; Farhad Rezaei; Somayeh Jalilvand; Nastaran Ghavami; Mahmoud Mahmoudi; Ramin Abiri; Nasim Kondori; Rakhshande Nategh; Talat Mokhtari Azad
Journal:  Iran Red Crescent Med J       Date:  2015-12-19       Impact factor: 0.611

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.